-+ 0.00%
-+ 0.00%
-+ 0.00%

Y-MABS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL EVALUATING CD38-SADA PRE-TARGETED RADIOIMMUNOTHERAPY IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Reuters·04/25/2025 11:35:00

Please log in to view news